KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $237.7 million.

  • Charles River Laboratories International's Current Deferred Revenue fell 5.65% to $237.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.7 million, marking a year-over-year decrease of 5.65%. This contributed to the annual value of $283.0 million for FY2024, which is 3.66% up from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's Current Deferred Revenue is $237.7 million, which was down 11.41% from $268.3 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Current Deferred Revenue ranged from a high of $283.0 million in Q4 2024 and a low of $213.0 million during Q1 2021.
  • Its 3-year average for Current Deferred Revenue is $258.0 million, with a median of $256.4 million in 2024.
  • As far as peak fluctuations go, Charles River Laboratories International's Current Deferred Revenue surged by 35.75% in 2021, and later declined by 5.65% in 2025.
  • Quarterly analysis of 5 years shows Charles River Laboratories International's Current Deferred Revenue stood at $219.7 million in 2021, then rose by 20.28% to $264.3 million in 2022, then rose by 3.31% to $273.0 million in 2023, then climbed by 3.66% to $283.0 million in 2024, then fell by 5.65% to $237.7 million in 2025.
  • Its Current Deferred Revenue stands at $237.7 million for Q3 2025, versus $268.3 million for Q2 2025 and $250.5 million for Q1 2025.